Tykerb lapatinib regulatory update

The U.K.'s NICE issued a new preliminary appraisal recommending against the use of GlaxoSmithKline's Tyverb lapatinib in combination with capecitabine to treat previously treated patients with advanced or metastatic breast cancer whose tumors overexpress HER2, except in clinical trials. The appraisal is in line with the agency's March final appraisal determination, which NICE reconsidered following an appeal by GSK (see BioCentury, March 9). ...